This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

CRISPR/cas13-medIated RNA tarGeting tHerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06031727
Recruitment Status : Recruiting
First Posted : September 11, 2023
Last Update Posted : November 13, 2023
Tianjin Medical University Eye Hospital
Eye & ENT Hospital of Fudan University
Information provided by (Responsible Party):
HuidaGene Therapeutics Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : June 27, 2025